483
Bora Pharmaceuticals Injectables IncFDA 483 - Bora Pharmaceuticals Injectables Inc - August 27, 2010
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Cangene bioPharma Inc. in Baltimore, MD, revealed significant deficiencies in quality assurance, aseptic processing, and facility maintenance. The firm failed to thoroughly investigate product discrepancies, maintain adequate visual inspection programs, and ensure proper material segregation and preventative maintenance for critical systems. These issues indicate a lack of robust controls over manufacturing processes and product quality.
Open in Dashboard
ID · 053d423a-ee3b-4474-95eb-e7981f3b1e37